

## Special Issue

# Advances in Rabies Vaccination

### Message from the Guest Editors

Rabies remains one of the most lethal zoonotic diseases, causing an estimated 59,000 human deaths annually. Recent advancements in reverse genetics, structural vaccinology, mRNA vaccine platforms, and monoclonal antibody cocktails are reshaping our arsenal against the rabies virus and other lyssaviruses. Additionally, novel biologics for post-exposure prophylaxis, thermostable oral vaccines for wildlife reservoirs, and machine-learning-assisted risk assessment tools are extending protection to previously unreachable populations.

Our goal is to assemble **original research and reviews that together provide a comprehensive overview of current progress and future directions in rabies prevention and control.**

**Research areas of interest include the following:**

- Immunological processes associated with rabies vaccines and correlates of protection;
- Rabies vaccine platforms;
- Therapeutic monoclonal antibodies and passive immunization;
- Thermostable and oral baits for wildlife and dog vaccination campaigns;
- Studies on rabies transmission dynamics and vaccine coverage;
- Optimization of post-exposure prophylaxis in resource-limited settings;
- Innovative delivery systems.

---

### Guest Editors

Dr. Ye Feng

Dr. Ming Zhou

Dr. Susan M. Moore

---

### Deadline for manuscript submissions

31 August 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/253031](https://mdpi.com/si/253031)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).